In contrast, in chronic myeloid leukemia, the initiating event is represented by BCR-ABL, while in several other myeloid cancers the initiating events are PDGFR translocations, so therapy in those cases would target in the initiating events. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.